Clinical overview of metronomic chemotherapy in breast cancer-Reference-Cited by-同舟云学术

Clinical overview of metronomic chemotherapy in breast cancer

Published:2015-08-04 Issue:11 Volume:12 Page:631-644
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Munzone Elisabetta,Colleoni Marco

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://www.nature.com/articles/nrclinonc.2015.131.pdf

Reference147 articles.

1. Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000).

2. Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886 (2000).

3. Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000).

4. Colleoni, M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73–80 (2002).

5. Orlando, L. et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 17, 961–967 (2006).

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promotion of tumor angiogenesis and growth induced by low-dose antineoplastic agents via bone-marrow-derived cells in tumor tissues;Frontiers in Pharmacology;2024-07-25

2. Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence;Cancer Letters;2024-07

3. Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology;Frontiers in Veterinary Science;2024-06-06

4. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy;Frontiers in Cell and Developmental Biology;2024-05-15

5. Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence;2024-04-30